Drug Profile
Research programme: PPAR alpha agonists - MaxoCore Pharmaceuticals
Alternative Names: MC-3001; PPAR alpha agonists research programme - MaxoCore PharmaceuticalsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MaxoCore Pharmaceuticals
- Class Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Lipid metabolism disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in USA (PO)
- 12 Jan 2011 This programme is in active development
- 07 Dec 2010 Research programme: PPAR alpha agonists - MaxoCore Pharmaceuticals is available for licensing as of 07 Dec 2010. http://www.maxocore.com